摘要
目的:探究新辅助化疗治疗结直肠癌患者的效果及对肿瘤标志物的影响。方法:选取2016年1月-2019年1月在天门市第一人民医院治疗的104例结直肠癌患者为研究对象,应用随机数字表法分为A组(n=52)及B组(n=52)。B组行常规腹腔镜手术治疗,A组在腹腔镜手术前加用新辅助化疗,对比两组的肿瘤标志物指标水平、免疫功能指标水平、肿瘤控制率及2年无病生存率。结果:治疗前,两组的癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、甲胎蛋白(AFP)比较,差异均无统计学意义(P>0.05);治疗后,两组的三项指标均较治疗前下降,且A组均低于B组,差异均有统计学意义(P<0.05)。治疗前,两组的CD3^(+)、CD4^(+)、CD8^(+)水平比较,差异均无统计学意义(P>0.05);治疗后,两组的CD3^(+)、CD4^(+)水平均较治疗前升高,且A组均高于B组;CD8^(+)均较治疗前降低,且A组低于B组,差异均有统计学意义(P<0.05)。A组肿瘤控制率(88.46%)高于B组(71.15%),差异有统计学意义(P<0.05)。A组的2年无病生存率(78.85%)高于B组(59.62%),差异有统计学意义(P<0.05)。结论:新辅助化疗治疗结直肠癌患者效果优异,可调节癌症相关肿瘤标志物的表达,减轻机体免疫功能损伤,改善远期预后。
Objective:To investigate the efficacy of neoadjuvant chemotherapy in the treatment of patients with colorectal cancer and the effect on tumor markers.Method:A total of 104 patients with colorectal cancer admitted to Tianmen First People’s Hospital from January 2016 to January 2019 were selected and divided into group A(n=52)and group B(n=52)by applying the random number table method.group B was treated with conventional laparoscopic surgery and group A was treated with neoadjuvant chemotherapy before laparoscopic surgery.The tumor marker index levels,immune function index levels,tumor control rate and 2-year disease-free survival rate were compared between the two groups.Result:Before treatment,there were no significant differences in carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and alpha-fetoprotein(AFP)between the two groups(P>0.05);after treatment,the three indexes in both groups decreased compared with those before treatment,and those in group A were lower than those in group B,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in CD3^(+),CD4^(+),CD8^(+)levels between the two groups(P>0.05);after treatment,the levels of CD3^(+),CD4^(+)increased in both groups compared with those before treatment,and those in group A were higher than those in group B;CD8^(+)decreased compared with those before treatment,and that in group A was lower than that in group B,the differences were statistically significant(P<0.05).The tumor control rate in group A(88.46%)was higher than that in group B(71.15%),the difference was statistically significant(P<0.05).2-year disease-free survival rate in group A(78.85%)was higher than that in group B(59.62%),the difference was statistically significant(P<0.05).Conclusion:Neoadjuvant chemotherapy has excellent effects in treating patients with colorectal cancer,regulating the expression of cancer-related tumor markers,reducing the damage of body immune function,and improving long-term prognosis.
作者
曾科
ZENG Ke(Tianmen First People’s Hospital,Hubei Province,Tianmen 431700,China)
出处
《中国医学创新》
CAS
2022年第34期61-64,共4页
Medical Innovation of China
关键词
新辅助化疗
结直肠癌
肿瘤标志物
免疫功能
Neoadjuvant chemotherapy
Colorectal cancer
Tumor markers
Immune function